Loading clinical trials...
Loading clinical trials...
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Allergan
NCT06289491 · Glaucoma, Glaucoma, Open-Angle
NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more
NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension
NCT05902871 · Primary Open Angle Glaucoma, Ocular Hypertension, and more
NCT05885022 · Glaucoma, Open-Angle
Berlin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions